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Abstract
Congenital long QT syndrome (LQTS) is a hereditary cardiac disease characterized by a prolongation of
the QT interval at basal ECG and by a high risk of life-threatening arrhythmias. Disease prevalence is
estimated at close to 1 in 2,500 live births.
The two cardinal manifestations of LQTS are syncopal episodes, that may lead to cardiac arrest and sudden
cardiac death, and electrocardiographic abnormalities, including prolongation of the QT interval and T
wave abnormalities. The genetic basis of the disease was identified in the mid-nineties and all the LQTS
genes identified so far encode cardiac ion channel subunits or proteins involved in modulating ionic
currents. Mutations in these genes (KCNQ1, KCNH2, KCNE1, KCNE2, CACNA1c, CAV3, SCN5A, SCN4B)
cause the disease by prolonging the duration of the action potential. The most prevalent LQTS variant
(LQT1) is caused by mutations in the KCNQ1 gene, with approximately half of the genotyped patients
carrying KCNQ1 mutations.
Given the characteristic features of LQTS, the typical cases present no diagnostic difficulties for physicians
aware of the disease. However, borderline cases are more complex and require the evaluation of various
electrocardiographic, clinical, and familial findings, as proposed in specific diagnostic criteria. Additionally,
molecular screening is now part of the diagnostic process.
Treatment should always begin with β-blockers, unless there are valid contraindications. If the patient has
one more syncope despite a full dose β-blockade, left cardiac sympathetic denervation (LCSD) should be
performed without hesitation and implantable cardioverter defibrillator (ICD) therapy should be
considered with the final decision being based on the individual patient characteristics (age, sex, clinical
history, genetic subgroup including mutation-specific features in some cases, presence of ECG signs –
including 24-hour Holter recordings – indicating high electrical instability).
The prognosis of the disease is usually good in patients that are correctly diagnosed and treated. However,
there are a few exceptions: patients with Timothy syndrome, patients with Jervell Lange-Nielsen syndrome
carrying KCNQ1 mutations and LQT3 patients with 2:1 atrio-ventricular block and very early occurrence
of cardiac arrhythmias.
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Background
The congenital long QT syndrome (LQTS) is a relatively
uncommon but important clinical disorder. Since 1975
[1] it includes under the unifying name of "Long QT syn-
drome" two hereditary variants. One is associated with
deafness [2,3] and one is not [4,5]; they are referred to as
the Jervell and Lange-Nielsen syndrome (J-LN) and as the
Romano-Ward syndrome (R-W), respectively. Long-QT
syndrome has been subdivided into types based on the
gene in which causative mutations occur. The most preva-
lent forms are LQT1 and LQT2 (due to mutations in
potassium channels), and LQT3 (due to a sodium channel
mutation).
The clinical manifestations of the disease are rather dra-
matic as they involve syncopal episodes, which often
result in cardiac arrest and sudden death and usually occur
in conditions of either physical or emotional stress in oth-
erwise healthy young individuals, mostly children and
teenagers. The high lethality among symptomatic and
untreated patients in the presence of very effective thera-
pies makes unacceptable the existence of symptomatic
and undiagnosed patients. The genetic findings of the last
15 years have made of LQTS a unique paradigm for genet-
ically mediated sudden cardiac death that allows to corre-
late genotype and phenotype, and provides a direct bridge
between molecular biology and clinical cardiology.
Epidemiology
Initially considered as a very rare condition, already in
1975 [1] we suggested that LQTS "could be more unrecog-
nized than rare". When coming, however, to actual num-
bers everything seemed to go and the prevalence was
assumed to be anywhere between 1/5,000 [6] to 1/20,000
[7], with most investigators settling for 1/10,000 [8].
Importantly, none of these estimates was based on actual
data.
The first data-driven indication of the prevalence of LQTS
is coming from the largest prospective study of neonatal
electrocardiography ever performed [9]. An electrocardi-
ogam (ECG) was recorded in 44,596 infants at 3–4 weeks
of age. Among them, 1.4% had a corrected QT (QTc)
interval between 440 and 469 ms and 0.7/1,000 had a
QTc ≥ 470 ms, regarded as markedly prolonged by the
European Task Force on Neonatal Electrocardiography
[10]. In the latter group (n = 31), more than 90% of
infants underwent molecular screening and LQTS disease-
causing mutations were found in 13 of 28 (46%) [9]. As
almost 50% of the infants with QTc ≥ 470 ms (0.7/1,000)
are affected by LQTS, and as at least some (number being
currently defined by extensive molecular screening) of the
infants with QTc between 440 and 469 ms are also likely
to be affected, it follows that the prevalence of LQTS must
be close to 1/2,500 at least. This is probably a bit of an
underestimate because we have postulated first [11] and
demonstrated later [12,13] that there is a significant
number of silent mutation carriers (QTc < 440 ms) that
actually ranges between 10% and 36% according to geno-
type. For the first time the prevalence of a cardiac disease
of genetic origin has been quantified on the basis of actual
data.
Clinical description
Romano-Ward syndrome
The two cardinal manifestations of LQTS are syncopal epi-
sodes and electrocardiographic abnormalities.
Cardiac events and their relation to genotype
The syncopal episodes are due to Torsade-de-Pointes
(TdP), a polymorphic ventricular tachycardia with a char-
acteristic twist of the QRS complex around the isoelectric
baseline, often degenerating into ventricular fibrillation.
TdP or ventricular fibrillation can initiate without changes
in heart rate and without specific sequences such as
"short-long-short" interval, even though long pauses in
LQTS patients increase the probability of TdP [14].
While it had been known for quite sometime that
although most patients would develop their symptoms
under stress, it was also known that in a minority of cases
these life-threatening cardiac events could occur at rest.
The reason(s) for these different patterns remained
obscure until molecular biology allowed to distinguish
between different genotypes. As predicted by their impair-
ment on the IKs current (essential for QT shortening dur-
ing increases in heart rate), most of the events of LQT1
patients occur during exercise or stress [15]. Conversely,
most of the events of LQT2 patients occur during emo-
tional stress such as auditory stimuli (sudden noises and
telephone ringing, especially while at rest) while for LQT3
patients they occur during sleep or at rest [15].
A higher risk has been reported in the post-partum period
[16]. Even here genotype is important because risk is
higher for LQT2 than for LQT1 patients [17,18]. In our
opinion, the highest risk for LQT2 women is at least in
part related to sleep disruption; accordingly, we recom-
mend not only to continue with full dose of β-blockers
but we consider important that husbands contribute to
feed the infants nighttime thus allowing a fair amount of
uninterrupted sleep for their LQT2 wives.
Electrocardiographic aspects
The bizarre electrocardiogram of many LQTS patients
should be easily recognized (Fig. 1). Clearly, there is much
more than a mere prolongation of ventricular repolariza-
tion. The T wave has several morphologic patterns easily
recognizable on the basis of clinical experience. They are
difficult to quantify but very useful for diagnosis.Orphanet Journal of Rare Diseases 2008, 3:18 http://www.ojrd.com/content/3/1/18
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QT interval duration
The Bazett's correction for heart rate remains a very useful
clinical tool despite unrelenting criticism. At slow and fast
rates it is important to be aware of hyper- and of under-
correction. Traditionally, QTc values in excess of 440 ms
are considered prolonged; however, values up to 460 ms
may still be normal among females [19]. The longer QT
values present among women [19] become evident only
after puberty but are absent at birth [20], suggesting a role
for hormonal changes. Exceptions exist and syncopal epi-
sodes occur also in patients with modest QT prolongation
and even with a normal QT interval, but, in general,
longer the QT greater is the risk for malignant arrhythmias
and multiple evidence indicates that when QTc exceeds
500–550 ms there is a definite increase in risk [13,21].
The initial and understandable concept that QT prolonga-
tion was the essential cornerstone of LQTS was challenged
by Schwartz in the 80s [11]. Theoretical considerations
led him in 1980 and 1985 [11,22] to propose that some
patients might be affected by LQTS and, nonetheless, have
a normal QT interval on the surface electrocardiogram.
Different T wave morphologies in affected members of the same family Figure 1
Different T wave morphologies in affected members of the same family. The proband had a documented cardiac 
arrest as first manifestation of LQTS. The basal ECG shows deep negative T waves in the precordial leads and a very prolonged 
QTc. His sister is still asymptomatic with typical bi-phasic T waves. His father, with notched T waves and a QTc 584 ms, has 
had 2 syncopal episodes. The arrows point to examples of notched T wave. [Reprinted from: Schwartz PJ, Priori SG, Napolitano C: 
The long QT syndrome. In: CARDIAC ELECTROPHYSIOLOGY. FROM CELL TO BEDSIDE. III EDITION (Zipes DP and Jalife J, Eds.) WB 
Saunders Co., Philadelphia, pp. 597–615, 2000 – with permission from Elsevier].Orphanet Journal of Rare Diseases 2008, 3:18 http://www.ojrd.com/content/3/1/18
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The validity of this unorthodox concept has been proven
by the existence of mutation carriers with a normal QT
interval [12,13,23], as a consequence of low penetrance.
This concept has important practical and medico-legal
implications because, for example, it no longer allows a
cardiologist to state that a sibling of an affected patient
with a normal QTc "is definitely not affected by LQTS".
T wave morphology
In LQTS not only is the duration of repolarization that is
altered, but also its morphology. The T wave is often
biphasic or notched (Fig. 1), suggesting regional differ-
ences in the time course of ventricular repolarization.
These abnormalities are particularly evident in the precor-
dial leads and contribute to the diagnosis of LQTS; they
often are more immediately striking than the sheer pro-
longation of the QT interval.
T wave alternans
Beat-to-beat alternation of the T wave, in polarity or
amplitude, may be present at rest for brief moments but
most commonly appears during emotional or physical
stresses and may precede TdP (Fig. 2). It is a marker of
major electrical instability and it identifies patients at par-
ticularly high risk in whom reassessment of therapy
should be prompted.
Sinus pauses
Several LQTS patients have sudden pauses in sinus
rhythm exceeding 1.2 seconds that are not related to sinus
arrhythmia [11] and may contribute to the initiation of
arrhythmias in LQTS patients. Their occurrence in LQT3
patients represents an important warning signal, which
requires reinforcing safety measures.
Heart rate and its reflex control
In 1975 Schwartz et al. [1] called attention to the presence
of a lower than normal heart rate in many patients, a phe-
nomenon particularly striking in children. During exer-
cise, several LQTS patients reach a heart rate level lower
than that achieved by healthy controls matched by age
and sex.
Recently, Brink et al. [24] and Schwartz et al. [25] in a large
South African LQT1 founder population, in which all the
affected members carry the KCNQ1-A341V mutation, pro-
vided the novel evidence that faster basal heart rates and
brisk autonomic responses are associated with a greater
probability of being symptomatic. This likely depends on
the fact that LQT1 patients have an impaired ability to
shorten their QT interval during heart rate increases
because of the mutation-dependent impairment in IKs, the
current essential for QT adaptation. Whereas among
patients with a major arrhythmogenic substrate (QTc >
500 ms) heart rate is rather unimportant, among patients
with a less severe arrhythmogenic substrate (QTc ≤ 500
ms) those in the lower tertile of heart rate are more fre-
quently asymptomatic (Fig. 3). Furthermore, relatively
low values of baroreflex sensitivity – an index of the abil-
ity to respond with brisk increases in either vagal or sym-
pathetic activity – were found to be associated with a
reduced probability of being symptomatic. Indeed, the
lack of QT shortening during sudden heart rate increases
favors the R-on-T phenomenon and initiation of ventricu-
lar tachycardia/ventricular fibrillation, while sudden
pauses elicit early afterdepolarizations in LQTS patients
that can trigger TdP. Blunted autonomic responses,
revealed by relatively low values of baroreflex sensitivity,
imply a reduced ability to change heart rate suddenly
which appears to be a protective mechanism for LQT1
patients.
Jervell and Lange-Nielsen syndrome
The Jervell and Lange-Nielsen (J-LN) syndrome is the
recessive variant of long QT syndrome, due to the pres-
ence of two homozygous or compound heterozygous
mutations on either the KCNQ1  or  KCNE1  genes
[3,26,27].
At first glance, the only clinical difference between the two
variants (J-LN and R-W variants) lies in the fact that J-LN
patients suffer also from congenital deafness. However, a
5-year-old patient affected by LQTS with congenital deafness Figure 2
5-year-old patient affected by LQTS with congenital 
deafness. Tracing recorded during a syncopal episode. T 
wave alternans precedes the onset of torsade de pointes. In 
this case, it is also evident that TdP is not preceded by a 
pause. (From C. Pernot: Le syndrome cardio-auditif de Jervell et 
Lange-Nielsen. Aspects electrocardiographiques. Proc Ass Europ 
Paediat Cardiol 1972, 8:28–36).Orphanet Journal of Rare Diseases 2008, 3:18 http://www.ojrd.com/content/3/1/18
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large cooperative study providing detailed clinical infor-
mation on 187 J-LN patients has allowed the recognition
of clear differences versus the other types of LQTS includ-
ing LQT1, the variant which shares with J-LN an impair-
ment in the IKs current. The J-LN is, with the possible
exceptions of the very rare forms of LQTS with congenital
atrioventricular (AV) block and with syndactyly, the most
severe of the major variants of LQTS. Almost 90% of the
patients have cardiac events, 50% become symptomatic
by age of 3 years, their average QTc is markedly prolonged
(557± 65 ms), and they become symptomatic much ear-
lier than any other major genetic subgroup of LQTS (Fig.
4A). Within the group of J-LN patients it has been possible
to identify subgroups at lower risk, namely those with a
QTc < 500 ms and those without syncope in the first year
of life [3]. Even though the clinical diagnosis of J-LN is
rather straightforward, it is important to genotype all
these patients because it has been shown by Schwartz et al.
[3] that the smaller group with KCNE1 mutations has a
markedly less severe clinical course than that with muta-
tions on KCNQ1 (Fig. 4B). This should influence thera-
peutic management.
The therapeutic approach to J-LN patients is complicated
by the early age at which most of these patients become
symptomatic and especially by the fact that β-blockers
appear to have only limited efficacy. Also left cardiac sym-
pathetic denervation (LCSD), employed in only a few
patients, does not appear as effective in other LQTS
patients. These data suggest that for many J-LN patients an
implantable cardioverter defibrillator (ICD) should be
seriously considered, in addition to the traditional thera-
pies. For the subgroups at lower risk, as described above,
it may be logical to postpone a decision to implant an ICD
until age 8–10.
Etiology
Following the identification, in 1995 and 1996, of the first
three LQTS genes associated with the most frequently
encountered LQTS variants called respectively LQT1,
LQT2, and LQT3, there has been a flourishing of identifi-
cations of genes proven or just thought to be associated
with LQTS [28-30]. This includes the genes for LQT4
through LQT10 (Table 1).
Unfortunately, haste or enthusiasm has created a termi-
nology problem because not all of these genes can be truly
regarded as responsible for LQTS. Specifically, we con-
sider that what have been called LQT4 [31] and LQT7 [32]
(Andersen-Tawil syndrome) are complex clinical disor-
ders in which a more or less modest prolongation of the
QT interval – especially in the Andersen-Tawil syndrome
[33] – is only a secondary epiphenomenon and should
not be regarded as part of LQTS. LQT5, LQT6 and LQT8,
although rare, are certainly part of LQTS. For LQT9 and
LQT10, there are only preliminary descriptions and at this
time should be regarded as putative forms of LQTS.
The main characteristic of all the LQTS genes identified so
far is to encode cardiac ion channel subunits or, as in the
case of the newly described CAV3, to modulate ionic cur-
rents: hence, the use of the word "channelopathy" to indi-
cate the group of diseases to which LQTS belongs.
KCNQ1 (LQT1) and KCNE1 (LQT5)
The delayed rectifier current (IK) is a major determinant of
the phase 3 of the cardiac action potential. It comprises
two independent components: one rapid (IKr) and one
slow, (IKs).
Differential risk for arrhythmic events among Mutation Car- riers (MCs) according to resting heart rate off- βB and QTc Figure 3
Differential risk for arrhythmic events among Muta-
tion Carriers (MCs) according to resting heart rate 
off- βB and QTc. The dashed horizontal line represents the 
predefined cut-off for QTc (≤ or > 500 ms) whereas the 
dashed vertical line corresponds to the first tertile (≤ 60 
bpm) of the heart rate values distribution. It is evident that in 
the group of patients with a QTc ≤ 500 ms those the first 
tertile (heart rate ≤ 60 bpm) were less frequently sympto-
matic compared to MCs in the other two tertiles (OR 0.19, 
95%CI 0.04–0.79, p = 0.023). This figure also provides evi-
dence that a QTc > 500 ms represents a more severe 
arrhythmogenic substrate in our population based on the fact 
that 15 of 16 (94%) MCs with a QTc > 500 ms were sympto-
matic. (Reprinted from ref. [25] with permission from Lippincott 
Williams and Wilkins).Orphanet Journal of Rare Diseases 2008, 3:18 http://www.ojrd.com/content/3/1/18
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The KCNQ1 gene and the KCNE1 gene encode respec-
tively the alpha (KvLQT1) and the β (MinK) subunit of the
potassium channel conducting the IKs current.  KCNQ1
mutations are found in the LQT1 variant of LQTS which is
also its most prevalent form. Approximately half of the
genotyped patients carry a mutation on this gene.
Homozygous or compound heterozygous mutations of
KCNQ1  have been associated with the recessive Jervell
and Lange-Nielsen form of LQTS (JLN1). LQT5 is an
uncommon variant of LQTS caused by mutations in the
KCNE1 gene: it accounts for approximately 2–3% of all
genotyped LQTS patients. Mutations in the KCNE1 gene
cause both Romano-Ward (LQT5) and Jervell and Lange-
Nielsen (JLN2) syndromes.
KCNH2 (LQT2) and KCNE2 (LQT6)
The KCNH2 gene and the KCNE2 gene encode respec-
tively the alpha (HERG – Human Ether-a-go-go Related
Gene) and the β (MIRP) subunit of the potassium channel
conducting the IKr current. This is the second most com-
mon variant of LQTS accounting for 35–40% of muta-
tions in LQTS genotyped patients. Functional expression
studies have demonstrated that mutations in the KCNH2
gene cause a reduction of IKr current.  KCNH2  mutants
have a reduced function compared to the wild type pep-
tides, therefore IKr channels that incorporate mutated sub-
units carry a reduced IKr repolarizing current. Defective
proteins may either cause a dominant negative effect on
the wild-type subunits or they may not interfere with the
function of the normal subunits thus causing haploinsuf-
Table 1: Long QT syndrome (LQTS) subtypes, disease-associated genes and prevalence
LQTS subtypes Gene Prevalence (% of all 
genotyped cases)
LQT1 and JLN1 (AR) KCNQ1 >50
LQT2 KCNH2 35–40
LQT3 SCN5A 10–15
LQT4 ANK2
LQT5 (RWS) and JLN2 KCNE1
LQT6 KCNE2
LQT7 (Andersen-Tawil syndrome)* KCNJ2
LQT8 (Timothy syndrome) CACNA1c
LQT9 CAV3
LQT10 SCN4B
Abbreviations: LQTS = Long QT syndrome; JLN = Jervell and Lange-Nielsen syndrome; RWS = Romano-Ward syndrome; AR = autosomal 
recessive
* We consider the Andersen-Tawil syndrome to be a disorder different from LQTS (see ref. [78])
(A) Kaplan-Meier curves of event-free survival comparing JLN patients vs LQT1, LQT2 and LQT3 symptomatic patients Figure 4
(A) Kaplan-Meier curves of event-free survival comparing JLN patients vs LQT1, LQT2 and LQT3 symptomatic 
patients.(Modified from ref. [3] with permission from Lippincott Williams and Wilkins). (B) Kaplan-Meier curve of event-free sur-
vival in JLN patients with mutations in KCNQ1 or KCNE1 genes. (Reprinted from ref. [3] with permission from Lippincott Williams 
and Wilkins).Orphanet Journal of Rare Diseases 2008, 3:18 http://www.ojrd.com/content/3/1/18
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ficiency. Trafficking abnormalities have also been
reported as a consequence of KCNH2 mutations [34].
Mutations in the KCNE2 gene are found in the LQT6 var-
iant of LQTS. This gene encodes MiRP1 (MinK Related
Peptide 1), a small peptide that coassembles with the
HERG protein to form the IKr channel. There are only few
examples of KCNE2 mutations associated with LQTS.
SCN5A (LQT3) and SCN4B (LQT10)
The  SCN5A  gene encodes the protein of the cardiac
sodium channel. The Na+ channel protein is a relatively
large molecule that folds onto itself to surround the chan-
nel pore. The first SCN5A mutations identified were clus-
tered in the regions that regulate the inactivation of the
channel (ΔKPQ, R1623Q, N1325S). In-vitro  expression
studies [35] showed that these mutations cause an
increased late inward sodium current (INa). It was con-
cluded that Na+ channel mutations produce the LQTS
phenotype by inducing a "gain of function" leading to
increase in the Na+ inward current which prolongs action
potential duration. The prevalence of LQT3 among LQTS
patients is estimated to be 10–15%.
Recently, a mutation on the sodium channel subunit NaV
β4 was identified in an asymptomatic child with major
QT prolongation and 2:1 AV block [36]. The mutation
(L179F) leads to an increased window current with a
molecular phenotype consistent with LQT3. This might
become LQT10.
CACNA1c (LQT8) – Timothy syndrome
LQT8 is a rare variant of LQTS characterized by marked
QT interval prolongation, often presenting with 2:1 func-
tional atrioventricular block and macroscopic T wave
alternans, and syndactyly. LQT8 is highly malignant, and
10/17 (59%) of the children reported by Splawski et al.
[37] died at a mean age of 2.5 years. Some children with
Timothy syndrome also had congenital heart diseases,
immune deficiency, intermittent hypoglycemia, cognitive
abnormalities, and autism.
Molecular screening identified two missense mutation in
the voltage-gated calcium channel gene (CACNA1c), in all
probands analyzed [37], causing a reduced channel inac-
tivation responsible for calcium overload, a well known
mechanism for tissue damage and arrhythmias induction.
CAV3 (LQT9)
The CAV3 gene encodes the caveoline 3, a protein compo-
nent of caveolae and an integral membrane protein in
trans-Golgi-derived vesicles. Caveolins participate in
many important cellular processes, including vesicular
transport and signal transduction.
Four missense mutations in CAV3-encoded caveoline 3
were recently identified in four LQTS probands and in
none of the 400 reference alleles [38]. All the mutations
identified (T78M, F97C, K30R and L86P) produced a
gain-of-function, LQT3-like molecular/cellular pheno-
type, when expressed in human embryonic kidney (HEK)
cells stably expressing the SCN5A-encoded cardiac
sodium channel. CAV3 mutations were also implicated in
a few sudden infant death syndrome cases [39,40].
Diagnosis
Clinical diagnosis
Given the characteristic features of LQTS, the typical cases
present no diagnostic difficulty for the physicians aware of
the disease. However, borderline cases are more complex
and require the evaluation of multiple variables besides
clinical history and surface electrocardiogram. To over-
come these difficulties, diagnostic criteria were first pro-
posed in 1985 [22] and were subsequently updated in
1993 [41] and then again in 2006 [42].
The new diagnostic criteria are listed in Table 2, with rela-
tive points assigned to various electrocardiographic, clini-
cal, and familial findings. The score ranges from a
minimum value of 0 and a maximum value of 9 points.
Based on our experience, we have arbitrarily divided the
point score into three probability categories: 1) ≤ 1 point
= low probability of LQTS; 2) > 1 to 3.0 points = interme-
diate probability of LQTS; and 3) ≥ 3.5 points = high
probability of LQTS. As QTc overcorrects at fast heart
rates, additional diagnostic caution is necessary when
dealing with a patient with tachycardia or with infants.
These diagnostic criteria were conceived in the pre-molec-
ular era and should be used with common sense. Obvi-
ously, they cannot be of value in identifying the so called
"silent mutation carriers" who have a normal QT interval.
For these individuals, molecular screening is essential. The
main value of these clinical criteria is during a first contact
with a patient (when one attempts to verify the likelihood
of the presence of LQTS with potential therapeutic deci-
sions while molecular diagnosis could not be available for
at least a few months) and in clinical studies when a cer-
tain degree of uniformity in diagnosis is essential.
Molecular diagnosis
Who should be screened for LQTS
Molecular diagnosis should always be attempted in fami-
lies or individuals in whom the diagnosis of LQTS has
either been made or is suspected on sound clinical
grounds. When molecular diagnosis is successful
(70–80% of cases in our laboratory), it does conclusively
establish the disease state in clinically borderline individ-
uals and especially in apparently unaffected individuals.Orphanet Journal of Rare Diseases 2008, 3:18 http://www.ojrd.com/content/3/1/18
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As discussed earlier, the penetrance of the disease can be
low, therefore it is essential always trying to genotype the
proband in a LQTS family. Successful genotyping will
allow rapid screening of all family members and identifi-
cation of 10–35% of mutation carriers who may have a
normal QT interval, but may be anyhow at risk of life-
threatening arrhythmias if not appropriately diagnosed
and treated.
Molecular genetics and risk stratification
Molecular genetics contribute importantly to risk stratifi-
cation. In 1998 Zareba et al. [43] suggested that LQT1 and
LQT2 patients had more events than LQT3 patients but
that the events in the latter group had greater lethality.
These data were limited in part by the fact that they were
based on 38 families, with the possibility of excessive
weight by certain families. In 2003 Priori et al. [13] pub-
lished data on a truly representative population (647
patients of known genotype coming from 193 families).
The incidence of life-threatening events was lower among
LQT1 patients compared to the other genotypes, partly
because of the high prevalence of silent mutation carriers
(QTc < 440 ms); the risk was higher among LQT2 females
vs. males and LQT3 males vs. females. An important point
is that, independently of genotype, the quartiles of QTc
(<446 ms, between 447 and 468 ms; between 469 and
498 ms; >498 ms) provide very useful information con-
cerning risk of becoming symptomatic. It also became evi-
dent that among LQT1 carriers many (37%) are silent
mutation carriers and that the majority of LQT1 patients
goes through life without ever suffering cardiac events.
Despite a more serious clinical pattern, it has to be noted
that also among LQT2 and LQT3 patients almost half
remains asymptomatic; this fact is often forgotten as dra-
matically shown by the growing attitude, especially in the
US, to implant ICDs in asymptomatic individuals just
because they have been diagnosed as affected by LQTS.
Risk stratification guided by molecular genetics represents
a very active area of research and significant progress is
continuously being made. Donger et al. [43] have the
merit of having been the first to go beyond "the gene" and
to consider topology. In 1997 they suggested that muta-
tions located in the C-terminal region might be associated
with a less severe clinical phenotype, a suggestion
renewed in 2001 by Piippo et al. [44]. In 2002 Moss et al.
[45] indicated that LQT2 patients with mutations in the
pore region of KCNH2 were at higher risk compared with
patients with mutations in different region of the same
gene. In 2007 Moss et al. [46] demonstrated in 600 LQT1
patients that both the transmembrane location of the
mutations and their dominant-negative effect are inde-
pendent risk factors for cardiac events. Shortly afterwards,
still in 2007 Crotti et al. [47] carried one step further the
quest for genetic markers contributing to risk stratifica-
tion. In a collaborative study focusing on the hot spot
KCNQ1-A341V (a common mutation present worldwide
and responsible for a major founder effect in almost 25
South African families), they have demonstrated that the
unusually high clinical severity already reported by Brink
Table 2: 1993–2006 Long QT syndrome (LQTS) diagnostic criteria
POINTS
ELECTROCARDIOGRAPHIC FINDINGS #
A QTc^ > 480 ms 3
460 – 470 ms 2
450 – 459 (male) ms 1
B TORSADE DE POINTES * 2
C T WAVE ALTERNANS 1
D NOTCHED T WAVE IN 3 LEADS 1
E LOW HEART RATE FOR AGE @ 0.5
CLINICAL HISTORY
A SYNCOPE * WITH STRESS 2
WITHOUT STRESS 1
B CONGENITAL DEAFNESS 0.5
FAMILY HISTORY $
A FAMILY MEMBERS WITH DEFINITE LQTS 1
B UNEXPLAINED SUDDEN CARDIAC DEATH BELOW AGE 30 AMONG IMMEDIATE FAMILY MEMBERS 0.5
# In the absence of medications or disorders known to affect these electrocardiographic features
^ QTc calculated by Bazett's formula where QTc = QT/√RR
* Mutually exclusive
@ Resting heart rate below the 2nd percentile for age
$ The same family member cannot be counted in A and B
SCORE: ≤ 1 point = low probability of LQTS
> 1 to 3 points = intermediate probability of LQTS
≥ 3.5 points = high probability of LQTSOrphanet Journal of Rare Diseases 2008, 3:18 http://www.ojrd.com/content/3/1/18
Page 9 of 16
(page number not for citation purposes)
et al. [24] for the South African families is present also
among LQT1 patients from different ethnic backgrounds
but carrying the same A341V mutation. Moreover, as
KCNQ1-A341V has a mild dominant-negative effect (the
current loss barely exceeds 50%) its striking clinically
severe phenotype is explained neither by the location
(transmembrane) nor by the functionally consequence of
the mutation (dominant-negative). This implies that the
current biophysical assessments of the electrophysiologi-
cal effects of LQTS-causing mutations do not provide all
the information necessary to make a complete genotype-
phenotype correlation. In this regard, the study by Crotti
et al. [47] paves the way toward a mutation-specific risk
stratification. In a near future, at least for certain cases, it
will become possible to implement a management specif-
ically directed to provide the best protection to LQTS
patients on the basis of their individual mutation.
Mutations located in the pore region of the protein are
usually associated with a more severe clinical phenotype
compared to mutation in the C-terminal region [45].
Unfortunately, the risk stratification process is not simple,
as additionally genetic variants may be present and may
modify clinical severity. An example is provided by an
LQT2 family with the C-terminal A1116V mutation. The
proband who had a severe form of the disease at variance
with her family-members all asymptomatic, was also the
only member of the family carrying the very common
KCNH2-K897T polymorphism, and genetic and electro-
physiological evidence indicates that K897T produces an
accentuation of the mutation-dependent IKr current loss
resulting in the unmasking of a clinically latent C-termi-
nal LQT2 mutation [48,49].
Relation with sudden infant deaths
Sudden infant death syndrome (SIDS) remains the lead-
ing cause of sudden death during the first year of life in the
western world. Despite a large number of theories mostly
focused on abnormalities in the control of respiratory or
cardiac function [50], the causes of SIDS remain largely
unknown. In 1976 Schwartz proposed that an undefined
number of SIDS victims might die because of an arrhyth-
mic death favored by a prolongation of the QT interval
with a mechanism similar to that of LQTS [51]. Few
months later Maron et al. also suggested that LQTS could
contribute to SIDS [52].
This hypothesis was tested by prospectively measuring the
QT interval during the first week of life in more than
33,000 infants and by following them for a possible
occurrence of SIDS [53]. There were 34 deaths, of which
24 were due to SIDS. The infants who died of SIDS had a
longer QTc (measured blindly to the outcome) than the
survivors and the victims from other causes. Moreover, 12
of the 24 SIDS victims but none of the other dead infants
had a prolonged QTc (defined a priori as exceeding 440
ms). The odds ratio for SIDS for infants with a prolonged
QTc was 41, reaching 47 for male infants. The unavoida-
ble conclusion of that study was that a QT prolongation
in the first week of life represents a major risk factor for
SIDS.
Subsequently, two proof-of-concept identifications of
LQTS-causing mutations in a victim of SIDS [54] and in
an infant who survived a typical episode of near-miss epi-
sode with documented ventricular fibrillation [55] paved
the way to two cohort studies. The first one found LQTS-
causing mutations in 5.2% of 68 white infants [56]. The
second [40], based on 201 SIDS victims and 187 controls,
all from Norway, identified functional [57,58] mutations
in LQTS genes in 9.5% (95% confidence intervals, 5.8 –
14.4) of the victims and in none of the controls. Consid-
ering that in 30% of unequivocal cases of LQTS no muta-
tions are found, it is likely that 11–13% of cases currently
labeled as SIDS are actually due to LQTS. As such, these
are preventable deaths.
These data obviously support the controversial concept of
neonatal ECG screening [59,60] according to the guide-
lines proposed by the Task Force of the European Society
of Cardiology [10]. The aim is the prevention of those
sudden deaths due to unrecognized LQTS which may
occur during the first few months of life or later on in life.
Importantly, such a screening is markedly cost-effective in
Europe [61].
Differential diagnosis
Typical cases of LQTS are so characteristic that differential
diagnosis is not even considered. When dealing with bor-
derline cases, the following conditions should be consid-
ered: vasovagal syncope, orthostatic hypotension,
arrhythmogenic right ventricular cardiomyopathy/dyspla-
sia (ARVC/D), catecholaminergic polymorphic ventricu-
lar tachycardia (CPVT), hypertrophic cardiomyopathy,
ventricular tachycardia, drug-induced long QT syndrome,
epilepsy.
Management including treatment
The trigger for most of the episodes of life-threatening
arrhythmias of LQTS is represented by a sudden increase
in sympathetic activity, largely mediated by the quantita-
tively dominant left cardiac sympathetic nerves [22].
Indeed, antiadrenergic therapies provide the greatest
degree of protection. However, some patients have synco-
pal episodes while being asleep or at rest, or when they
suddenly aroused from these states, and in some cases the
arrhythmias are pause-dependent. As discussed above, the
triggering conditions are largely gene-dependent [15].Orphanet Journal of Rare Diseases 2008, 3:18 http://www.ojrd.com/content/3/1/18
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Antiadrenergic interventions
β-adrenergic blockade
β-adrenergic blocking agents represent the first choice
therapy in symptomatic LQTS patients, unless specific
contraindications are present.
Propranolol is still the most widely used drug, at a daily
dosage of 2 to 3 mg/kg; sometime the dosage is increased
to 4 mg/kg. The main advantages of propranolol are its
lipophilicity that allows it to cross the blood-brain barrier,
and its well known tolerability for chronic therapy. Its
main disadvantages are the need of multiple daily admin-
istrations and the contraindications for patients with
asthma and diabetes. For these reasons nowadays nadolol
is used more frequently, as its longer half-life allows twice-
a-day administration, usually at 1 mg/kg/day. Atenolol
has been reported to be associated with clinical failures
more often than propranolol or nadolol. β-blockers rarely
result in excessive bradycardia, especially if the dosage is
very gradually increased over several weeks.
In a large number of patients of unknown genotype, mor-
tality on β-blocker therapy was 2%, and it was 1.6% when
limited to patients with syncope (no cardiac arrest) and
without events in the first year of life [62]. There is clear
evidence that β-blockers are extremely effective in LQT1
patients. Data from two large studies [63,64] indicate that
mortality is around 0.5% and sudden death combined
with cardiac arrest reaches 1%. The impairment in the IKs
current makes these patients particularly sensitive to cate-
cholamines and quite responsive to β-blockade. These
patients seldom need more than antiadrenergic therapy.
Compared to LQT1 patients, LQT2 patients have more
life-threatening events despite β-blockers, but most of
these are resuscitated cardiac arrest (6–7%) [63]. Among
LQT3 patients major events occur more frequently
(10–15%) despite β-blockers [15,63], and several of these
patients require additional therapies (see below). Also
many patients with Jervell and Lange-Nielsen syndrome
are not adequately protected by β-blockers [3].
Compliance is essential for LQTS patients treated with β-
blockers. Most of the so-called failures of β-blockers ther-
apy are due to incomplete compliance [64].
Left cardiac sympathetic denervation (LCSD)
Following a small incision in the left subclavicular region,
LCSD is performed by an extrapleural approach which
makes thoracotomy unnecessary. The average time for the
complete operation is 35–40 minutes [65]. LCSD requires
removal of the first four thoracic ganglia. There is no need
to ablate the cephalic portion of the left stellate ganglion.
In this way the Horner's syndrome (ptosis and miosis) can
almost always be avoided [65]. In approximately 30% of
patients there is a very modest (1–2 mm) ptosis which can
be noted only by close examination but fully escapes
notice in normal social interactions.
The data published in 1991 [66] were updated in 2004 to
include 147 LQTS patients who underwent LCSD during
the last 35 years [65]. These patients constituted a very
high risk group, as witnessed by the fact that 99% were
symptomatic, that their mean QTc was very long (563± 65
ms), that 48% had a cardiac arrest and especially that 75%
continued to have syncope despite full-dose β-blockers.
The data most relevant to clinical decisions nowadays are
those regarding patients without cardiac arrest (who cur-
rently properly receive an ICD) who suffer syncope
despite being treated with a full dose of β-blockers. Dur-
ing a mean follow-up of eight years there was a 91%
reduction in cardiac events. LCSD was associated with a
mean QTc shortening of 39 ms, pointing to an action on
the substrate as well as on the trigger. Mortality was 3% in
this high risk group. A post-surgery QTc < 500 ms pre-
dicted a very favorable outcome (Fig. 5). Practically of
great relevance is the fact that this series included five
patients who underwent LCSD due to multiple ICD
shocks and electrical storms: in this group, over a 4-year
follow-up there was a 95% decrease in the number of
shocks (from an average of 29 shocks/year) with a dra-
matic improvement in the quality of life of the patients
and of their families.
The major antifibrillatory efficacy of LCSD has been pre-
viously demonstrated in high-risk post-myocardial infarc-
tion patients [67], and very recently in patients with
Kaplan-Meier curves of event-free survival and survival  according to QTc interval after left cardiac sympathetic den- ervation in patients with only syncope, or aborted cardiac  arrest before left cardiac sympathetic denervation Figure 5
Kaplan-Meier curves of event-free survival and sur-
vival according to QTc interval after left cardiac sym-
pathetic denervation in patients with only syncope, 
or aborted cardiac arrest before left cardiac sympa-
thetic denervation. (Modified from ref. [65] with permission 
from Lippincott Williams and Wilkins).Orphanet Journal of Rare Diseases 2008, 3:18 http://www.ojrd.com/content/3/1/18
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catecholaminergic polymorphic ventricular tachycardia
not protected by β-blockers and receiving unnecessary
shocks by the ICD [68].
Whenever syncopal episodes recur despite a full-dose β-
blocking therapy, LCSD should be considered and imple-
mented whenever possible.
Cardiac pacing
The LQTS patients for whom cardiac pacing is indicated
are very few. In infants or young children with 2:1 AV
block this remains a reasonable choice, as a bridge to the
ICD. The fact that the onset of TdP is very often preceded
by a pause [14] might add to the rationale of using a pace-
maker as an adjunct to the therapy of some LQTS patients.
However, nowadays if a pacemaker is being considered, it
is probably more logical to implant an ICD with pacing
modes. In any case, pacemakers should never be used as a
sole therapy for LQTS.
Implantable cardioverter defibrillators (ICDs)
There has been a major increase, largely unjustified, in the
number of ICDs implanted in LQTS patients. It is uni-
formly agreed that in case of a documented cardiac arrest,
either on or off therapy, an ICD should immediately be
implanted. By contrast, there are strongly different opin-
ions regarding the use of ICDs in patients without cardiac
arrest.
The available data from both the US [69] and the Euro-
pean [70] ICD-LQTS Registries provide the disquieting
information that the majority of implanted patients had
not suffered a cardiac arrest and, moreover, that many had
not even failed β-blocker therapy. A recent multicenter
study went as far as indicating that in their protocol the
mere presence of a SCN5A mutation, even in a totally
asymptomatic individual, is sufficient for immediate ICD
implant; the authors added that none of their LQT3
patients has received shocks so far [71].
It should not be forgotten that the implantable defibrilla-
tor does not prevent occurrence of malignant arrhythmias
and that TdP are frequently self-terminating in LQTS, as
indicated by the high incidence of syncopal episodes with
spontaneous recovery. The recurrence of electrical storms
has led to suicidal attempts in teenagers and its high inci-
dence (>10%) in children has been considered by a large
group of US pediatric cardiologists as "devastating" [72].
The massive release of catecholamines, triggered by pain
and fear, that follows an ICD discharge in a conscious
patient – especially a young one – leads to further arrhyth-
mias and to further discharges which produce a dramatic
vicious circle. To overcome these limitations we have
designed a new algorithm for ICDs specifically tailored for
the young LQTS patients that is currently under clinical
evaluation. This includes, prior to discharge, sufficient
time to allow a spontaneous return to sinus rhythm after
onset of Torsade-de-Pointes/ventricular fibrillation and to
then automatically institute a period of relatively rapid
pacing to prevent reinitiation of life-threatening arrhyth-
mias and new shocks.
Special caution is necessary before choosing to implant an
ICD in a child with LQTS. Such a decision is seldom justi-
fied before a proper trial with combined antiadrenergic
therapy (i.e. full-dose β-blockade and LCSD), which pre-
vents sudden death in 96–97% of symptomatic and high-
risk patients [65] and which still allow an ICD implant in
case of a new syncope or cardiac arrest. On the other hand,
the nature of the disease is such that cardiac arrests may
recur and have lethal consequences. Thus, concerns for
the life of the patients and the interference of medico-legal
considerations represent a reality. The risk-benefit ratio of
an ICD should be clearly explained to the patient or to
his/her parents together with information on the pro and
cons of LCSD, to allow them the possibility of a choice.
Paradoxically, the decision to implant an ICD as an addi-
tional precaution even in a patient who appears to do well
with combined antiadrenergic therapy, has a certain logic
because such a patient has a low but not zero risk of car-
diac arrest. This makes cardioversions unlikely to occur
but the presence of the ICD may provide a means of sur-
vival against the unexpected episode of an otherwise
lethal arrhythmia. The need for several battery and leads
replacements remains a major problem with young
patients.
Our current policy is to implant an ICD always after a car-
diac arrest, always when requested by the patient, and
whenever syncope recurs despite β-blockade and LCSD.
The long QT syndrome is one of the leading cause of sud-
den cardiac death in young otherwise healthy individuals
and contributes significantly to SIDS. As very effective
therapies do exist, it is important to make a very early
diagnosis, i.e. with a program of neonatal ECG screening,
to be able to act in a preventive manner.
To make a correct diagnosis various electrocardiographic,
clinical, and familial findings must be taken into account
and specific diagnostic criteria have been developed
(Table 2). Additionally, molecular screening in LQTS is
now part of the diagnostic process, as in 70% of the
affected cases a mutation in the already known LQTS
genes can be identified.
The identification of the genetic defect responsible for the
disease in a family is also important allowing to identify
all affected family members at risk for life-threatening car-
diac arrhythmias, even those with a normal QTc (silentOrphanet Journal of Rare Diseases 2008, 3:18 http://www.ojrd.com/content/3/1/18
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mutation carriers). A proper example is that of a family
with a boy and a girl, the boy and one parent being clearly
affected (syncope and prolonged QTc). If the girl has a
normal QT interval and is incorrectly assumed to be unaf-
fected, she might later on be treated with one of the many
drugs that block the IKr current, and could develop TdP
and die. This would not be a bad luck; it would be the
direct responsibility of the physician who had not
attempted molecular screening in the mother or boy who
were clearly affected. Identification of the disease-causing
mutation would have allowed to rapidly establish beyond
doubt if the girl was or not a mutation carrier and this
would have saved her life.
The identification of the disease causing mutation is also
helpful in the risk stratification process, as not only the
gene [15] but also the specific site of the mutation [43-46]
and sometimes the specific mutation [24,47] can be asso-
ciated with a different risk for cardiac arrhythmias and dif-
ferent response to therapy. Therefore, the genetic data is
very useful for the correct management of these patients.
As a matter of fact, according to the genotype, different is
the response to β-blocker therapy (very good in LQT1, rea-
sonable in LQT2 and apparently poor in LQT3) and also
to conditions that could favor the occurrence of life-
threatening arrhythmias are different. LQT1 patients are at
higher risk during sympathetic activation, such as during
exercise and emotions. They should not be allowed to par-
ticipate in competitive sports. Swimming is particularly
dangerous, as 99% of the arrhythmic episodes associated
with swimming occur in LQT1 patients [15].
In LQT2 patients, some of whom have a tendency to lose
potassium, it is essential to preserve adequate potassium
levels. Oral K+ supplements in combination with K+ spar-
ing agents are a reasonable approach. As these patients are
at higher risk especially when aroused from sleep or rest
by a sudden noise [15,73], we recommend that tele-
phones and alarm clocks are removed from their bed-
rooms and, especially with children, whenever they have
to be wakened up in the morning, to do it gently and with-
out yelling. These rather gross management measures
actually constitute a form of gene-specific therapy.
The realization that SCN5A mutations producing LQT3
have a "gain-of-function" effect [35] has lent support to
our early suggestion [74] to test sodium channel blockers,
and especially mexiletine, as possible adjuvants in the
management of LQT3 patients [42,75-77]. Our current
policy is to test the effectiveness of mexiletine in all LQT3
patients by the acute oral drug test technique, which
requires administration of half the daily dose during con-
tinuous ECG monitoring. Within 90 minutes the peak
plasma concentration is reached and if the QTc is short-
ened by more than 40 ms then we add mexiletine to the
β-blocker therapy. As a matter of fact, in most LQT3
patients with mexiletine QTc shortens by more than
70–80 ms (Fig. 6)[78]. Even though there is no conclusive
evidence for a beneficial effect and definite failures have
occurred, there is also growing evidence of significant
benefit in a number of individual cases. Not all patients
carrying SCN5A mutations respond equally to mexiletine
[42]. There are cases of highly malignant forms that man-
ifest in infancy and are due to mutations causing a severe
electrophysiological dysfunction that are corrected by
both mexiletine and propranolol [42].
Interestingly, during heart rate increases, QTc shortens
more in LQT3 patients than among healthy controls [74]
and, indeed, normal physical activity may not need to be
restricted in LQT3 patients. They are at higher risk of death
at rest and especially nighttime. When these patients sleep
and are in a horizontal position, the onset of TdP pro-
duces a progressive but slow fall in blood pressure that
facilitates a noisy gasping preceding death. This has led
both LQT2 (also at risk while resting) and LQT3 patients
to be saved by a family member, such as the spouse sleep-
ing in the same bed. Accordingly, we recommend that
LQT2 and LQT3 patients have an intercom system in their
and – if young – in their parents bedrooms.
Finally, QT interval shortening, albeit encouraging, can-
not be assumed automatically to imply protection from
life-threatening arrhythmias. One should never forget the
tragic failures of the attempts to shorten QT by digitalis
[1]. The use of novel and experimental therapies should
not deprive symptomatic patients of therapies with estab-
lished protective effect.
Given the risk of approximately 12% of sudden death as
first manifestation of LQTS, we consider necessary to ini-
tiate β-blocker treatment in all patients, including those
still asymptomatic. Among the asymptomatic patients,
reasonable exceptions appear to be LQT1 males above age
20–25 because very rarely they become symptomatic
above this age, and adults with a QTc < 500 ms. LQT2
women seem to remain at risk throughout life and we rec-
ommend to treat them always. Patients with a normal QTc
(< 440 ms) appear to be at very low risk for life-threaten-
ing arrhythmias. In absence of clear follow-up data their
treatment is optional; the characterization of the muta-
tion could influence this choice.
Cardiac and non-cardiac drugs that block the IKr current
and thereby prolong the QT interval should always be
avoided by LQTS patients. A drugs list is published at Ari-
zona Center for Education and Research on Therapeutics
[79]. Such a list, updated every year, should be given to all
LQTS patients because their responsible physicians may
not be aware of these electrophysiological actions.Orphanet Journal of Rare Diseases 2008, 3:18 http://www.ojrd.com/content/3/1/18
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Conclusion
In conclusion, the sound data available, and decades of
clinical experience, dictate the therapeutic approach to the
patient affected by LQTS who already has had a syncopal
episode. Treatment should always begin with β-blockers,
unless there are valid contraindications. If the patient has
one more syncope despite full dose β-blockade, LCSD
should be performed without hesitation and ICD implant
should be considered with the final decision being based
on the individual patient characteristics (age, sex, previ-
ous history, genetic subgroup including sometime muta-
tion-specific features, presence of ECG signs – including
24-hour Holter recordings – indicating high electrical
instability). In the end, there is no substitute for careful
clinical judgment, accompanied by a thorough knowl-
edge of the several variants of this unique life-threatening
cardiac disorder, when the goal is to protect the patients
and at the same time to ensure their quality of life.
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